

STAT2-Defective Mutant Daudi (RST2) cell line

Catalogue number: 156502

Tool type:

Contributor

Inventor: Lawrence Pfeffer

Institute: The University of Tennessee Health Science Center

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: STAT2-Defective Mutant Daudi (RST2) cell line

Alternate name:

Class:

Conjugate:

Description: This cell line can be used to study drug resistance developed after treatment with interferon. Interferon therapy has been proved as a successful treatment for various types of cancer, however it develops resistance in patients. This cell line was not affected by the antiviral, antiproliferative, and gene-inducing actions of IFN.

Purpose:

Parental cell: Human Daudi Burkitt Lymphoma cell line

Organism: Human

Tissue: Blood

Model: Transgenic

Gender:

Isotype:

Reactivity:

Selectivity:

Host:

Immunogen:

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details: Isolated from IFN-sensitive Daudi cell line by growth in the continuous presence of IFN

Formulation:

Recommended controls: Human Daudi Burkitt Lymphoma parental line

Bacterial resistance:

Selectable markers:
Additional notes:

Patient details

Cancer subtype:
Cancer stage/grade:
Biopsy site:
Patient ethnicity:
Treatment history:

Engraftment details

Mice passaged?:
Engraftment site:
Sample type:
Host strain:
Histology:
Genetic data:

Target details

Target:
Target alternate names:
Target background:
Molecular weight:
Ic50:

Applications

Application:
Application notes:

Handling

Format: Frozen
Concentration:
Passage number:
Growth medium: RPMI1640 and 10% defined calf serum; Subculture 1:4 twice a week, maintain 1 and 10×10^5 cells/mL
Temperature:
Atmosphere:
Volume:

CancerTools.org

Storage medium:

Storage buffer:

Storage conditions:

Shipping conditions: Dry ice

Related tools

Related tools:

References

References: Izaguirre et al. 2013. J Biol Chem. 288(30):21802-14. PMID: 23744066.

CancerTools.org